公开(公告)号：US20170231941A1

公开(公告)日：2017-08-17

申请号：US15581966

申请日：2017-04-28

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Florian SCHOENHARTING ,  Bernd W. MUELLER ,  Joseph R. ROBINSON

IPC: A61K31/225 ,  A61K9/20 ,  A61K9/00

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

公开(公告)号：US20150272894A1

公开(公告)日：2015-10-01

申请号：US14561010

申请日：2014-12-04

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Roland Rupp

IPC: A61K9/28 ,  A61K31/225

CPC classification number: A61K9/28 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/215 ,  A61K31/225

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract translation: 包含含有一种或多种富马酸酯的腐蚀基质以及一种或多种速率控制剂的药物制剂，其中所述腐蚀基质的侵蚀允许所述富马酸酯的受控释放。

公开(公告)号：US20150024049A1

公开(公告)日：2015-01-22

申请号：US14209823

申请日：2014-03-13

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Florian SCHOENHARTING ,  Bernd W. MUELLER ,  Joseph R. ROBINSON

IPC: A61K31/225 ,  A61K9/28

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side effects.

Abstract translation: 本发明涉及包含富马酸酯作为活性物质的控释药物组合物。 该组合物适合用于治疗例如儿童。 牛皮癣或其他过度增生，炎性或自身免疫性疾病，并被指定以受控的方式释放富马酸酯，使得可以避免在口服给药时在胃肠道内的局部高浓度的活性物质，从而能够减少胃 - 肠道相关副作用。

公开(公告)号：US20140200272A1

公开(公告)日：2014-07-17

申请号：US14209584

申请日：2014-03-13

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Florian SCHOENHARTING ,  Bernd W. MUELLER ,  Joseph R. ROBINSON

IPC: A61K31/225 ,  A61K9/48

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

公开(公告)号：US20140199386A1

公开(公告)日：2014-07-17

申请号：US14209712

申请日：2014-03-13

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Florian SCHOENHARTING ,  Bernd W. MUELLER ,  Joseph R. ROBINSON

IPC: A61K31/225 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

公开(公告)号：US20140037720A1

公开(公告)日：2014-02-06

申请号：US13957117

申请日：2013-08-01

Applicant: Forward Pharma A/S

Inventor： Henrik Nilsson ,  Florian Schönharting ,  Bernd W. Müller ,  Joseph R. Robinson

IPC: A61K9/50 ,  A61K31/225 ,  A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to a method of treating a subject in need of treatment for multiple sclerosis including orally administering to the subject in need thereof a delayed release pharmaceutical composition using an increasing dose regimen, wherein an initial daily amount of drug administered is increased later to a higher daily amount and the pharmaceutical composition consists essentially of (a) dimethylfumarate and (b) one or more pharmaceutically acceptable excipients.

Abstract translation: 本发明涉及一种治疗需要治疗多发性硬化症的受试者的方法，包括向有需要的受试者口服给药使用增加剂量方案的延迟释放药物组合物，其中所施用药物的初始日剂量随后增加至 更高的每日量，并且药物组合物基本上由（a）富马酸二甲酯和（b）一种或多种药学上可接受的赋形剂组成。

公开(公告)号：US20130315993A1

公开(公告)日：2013-11-28

申请号：US13957147

申请日：2013-08-01

Applicant: Forward Pharma A/S

Inventor： Henrik Nilsson ,  Florian Schönharting ,  Bernd W. Müller ,  Joseph R. Robinson

IPC: A61K31/225 ,  A61K9/50 ,  A61K9/28

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release.

Abstract translation: 本发明具有一套工具。 试剂盒包括：（i）基本上由约120mg富马酸二甲酯和一种或多种药学上可接受的赋形剂组成的第一单位剂型，其中将富马酸二甲酯配制成延迟释放; 和（ii）基本上由约240mg富马酸二甲酯和一种或多种药学上可接受的赋形剂组成的第二单位剂型，其中将富马酸二甲酯配制成延迟释放。

公开(公告)号：US20170231943A1

公开(公告)日：2017-08-17

申请号：US15584439

申请日：2017-05-02

Applicant: Forward Pharma A/S

Inventor： Christin GALETZKA ,  Chris RUNDFELDT ,  Roland RUPP ,  Peder M. ANDERSEN

IPC: A61K31/225 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/28 ,  A61K9/2846 ,  A61P17/06

Abstract: The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF), More specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.

公开(公告)号：US20160206586A1

公开(公告)日：2016-07-21

申请号：US14914025

申请日：2014-08-26

Applicant: Forward Pharma A/S

Inventor： Christin GALETZKA ,  Chris RUNDFELDT ,  Roland RUPP ,  Peder M. ANDERSEN

IPC: A61K31/225 ,  A61K9/20 ,  A61K9/00 ,  A61K9/28

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/28 ,  A61K9/2846 ,  A61P17/06

Abstract: The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.

Abstract translation: 本发明涉及含有富马酸二甲酯（DMF）的药物组合物。 更具体地说，本发明涉及一种口服用于治疗牛皮癣的药物组合物，其通过在375mg±5％富马酸二甲酯的范围内施用较低的日剂量，其中药物制剂为侵蚀性基质片剂的形式。

公开(公告)号：US20140199388A1

公开(公告)日：2014-07-17

申请号：US14213673

申请日：2014-03-14

Applicant: Forward Pharma A/S

Inventor： Henrik NILSSON ,  Florian Schoenharting ,  Bernd W. Mueller ,  Joseph R. Robinson

IPC: A61K9/48 ,  A61K9/28 ,  A61K9/14 ,  A61K31/225

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.